Chronic myeloid leukemia

Score 7.7 = 7.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph1/Ph2NCT07604233 · M.D. Anderson Cancer Center · Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
• Ph2NCT07269470 · M.D. Anderson Cancer Center · Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
• Ph2NCT06817720 · M.D. Anderson Cancer Center · Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib

Score 3.8 = 3.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT05364762 · City of Hope Medical Center · Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
• Ph2NCT07582172 · City of Hope Medical Center · Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Score 3.6 = 3.2 leading Phase 2+ trials + 0.4 other trial roles + 0 talks + 0 posters. 8 of 9 trials are Phase 2+.

• Ph2NCT03263572 · M.D. Anderson Cancer Center · Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
• Ph2NCT06236724 · M.D. Anderson Cancer Center · Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
• Ph1NCT06088888 · Shenzhen TargetRx Co., Ltd. · TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients
• Ph2NCT01424982 · M.D. Anderson Cancer Center · Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
• Ph2NCT05007873 · M.D. Anderson Cancer Center · ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
• Ph2NCT01746836 · M.D. Anderson Cancer Center · Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
• Ph3NCT06423911 · Ascentage Pharma Group Inc. · Study of Olverembatinib (HQP1351) in Patients With CML-CP
• Ph2NCT02689440 · M.D. Anderson Cancer Center · Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
• Ph2NCT03147612 · M.D. Anderson Cancer Center · Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Score 3.6 = 3.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph2NCT07819396 · Fred Hutchinson Cancer Center · Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
• Ph1/Ph2NCT03670966 · Fred Hutchinson Cancer Center · 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
• Ph2NCT04195633 · Fred Hutchinson Cancer Center · Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Score 3.2 = 3.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT06597734 · M.D. Anderson Cancer Center · A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
• Ph2NCT06566742 · M.D. Anderson Cancer Center · A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07872709 · John Mascarenhas · Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07872709 · John Mascarenhas · Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07468916 · Jonsson Comprehensive Cancer Center · Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Score 2.8 = 2.7 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph1NCT04375631 · Fred Hutchinson Cancer Center · CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
• Ph2NCT07046078 · Fred Hutchinson Cancer Center · Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
• Ph2NCT03399773 · Fred Hutchinson Cancer Center · Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Score 2.4 = 2.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07493408 · The University of Hong Kong · Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

Score 2.2 = 2.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07128381 · M.D. Anderson Cancer Center · Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Score 2 = 2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06928662 · Fred Hutchinson Cancer Center · Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Score 1.9 = 1.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph1/Ph2NCT05322850 · University of Florida · Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
• Ph2NCT05800210 · University of Florida · Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

Score 1.9 = 1.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07022743 · Obafemi Awolowo University · Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy

Score 1.7 = 1.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06815003 · City of Hope Medical Center · Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Score 1.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT06001385 · Center for International Blood and Marrow Transplant Research · HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
• Ph2NCT04904588 · Center for International Blood and Marrow Transplant Research · HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Score 1.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06629584 · M.D. Anderson Cancer Center · Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Score 1.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06802315 · University of Illinois Chicago · Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

Score 1.5 = 1.4 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 3 of 4 trials are Phase 2+.

• Ph1NCT03896269 · M.D. Anderson Cancer Center · CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
• Ph1/Ph2NCT04493138 · M.D. Anderson Cancer Center · Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
• Ph1/Ph2NCT04734990 · M.D. Anderson Cancer Center · Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
• Ph1/Ph2NCT05038592 · M.D. Anderson Cancer Center · Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Score 1.5 = 0.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 1 posters. 1 of 1 trials are Phase 2+.

• ASH 2026 1987 (poster) · Week 96 interim analysis (IA) of efficacy and safety results in the Phase 2 ASC2ESCALATE trial: Asciminib (ASC) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) after 1 prior tyrosine kinase inhibitor (TKI)
• ASH 2026 1997 (poster) · Characterization of atypical breakpoints of BCR::ABL1 rearrangements in chronic myelogenous leukemia (CML) and other myeloid malignancies

• Ph2NCT04838041 · Medical College of Wisconsin · Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT06647862 · ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT06647862 · ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Score 1.4 = 1.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 4 of 4 trials are Phase 2+.

• Ph1/Ph2NCT04655755 · M.D. Anderson Cancer Center · Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
• Ph1/Ph2NCT04550442 · M.D. Anderson Cancer Center · Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
• Ph2NCT04239157 · M.D. Anderson Cancer Center · A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
• Ph1/Ph2NCT04160052 · M.D. Anderson Cancer Center · Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Score 1.4 = 0.4 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 3 of 5 trials are Phase 2+.

• Ph2NCT02396134 · City of Hope Medical Center · Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
• Ph1NCT07020533 · City of Hope Medical Center · A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
• Ph1NCT03560752 · City of Hope Medical Center · CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
• Ph2NCT02506933 · City of Hope Medical Center · Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
• Ph2NCT04060277 · City of Hope Medical Center · Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

Score 1.4 = 1.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06523556 · Uma Borate · Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Score 1.3 = 0.8 leading Phase 2+ trials + 0.5 other trial roles + 0 talks + 0 posters. 3 of 4 trials are Phase 2+.

• Ph1/Ph2NCT04140487 · M.D. Anderson Cancer Center · Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
• Ph1NCT06401603 · M.D. Anderson Cancer Center · A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
• Ph1/Ph2NCT03862157 · M.D. Anderson Cancer Center · Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
• Ph2NCT04188405 · M.D. Anderson Cancer Center · Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Score 1.3 = 1.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06013423 · Fred Hutchinson Cancer Center · Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Score 1.3 = 1.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06059391 · City of Hope Medical Center · CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Score 1.2 = 1.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT05768711 · Groupe Francophone des Myelodysplasies · Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
• Ph1/Ph2NCT03588078 · Groupe Francophone des Myelodysplasies · Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Score 1.2 = 1.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06368414 · Korean Society of Hematology · A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

Score 1.1 = 1.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06001385 · Center for International Blood and Marrow Transplant Research · HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Score 1 = 1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT05768711 · Groupe Francophone des Myelodysplasies · Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

Score 1 = 1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT05413915 · Sarit Assouline · Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 2 trials are Phase 2+.

• Ph1NCT07254793 · University of Arizona · Prophylactic DLI-X for Leukemia Relapse After HCT
• Ph1NCT02996773 · University of Arizona · Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07909733 · University of Wisconsin, Madison · Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07758218 · University of Wisconsin, Madison · Allogeneic iNKT Cell Therapy (agenT-797) After SCT

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT06904066 · National Cancer Institute (NCI) · Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Score 0.9 = 0.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT05884333 · Memorial Sloan Kettering Cancer Center · Cord Blood Transplant in Adults With Blood Cancers

Score 0.9 = 0.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT05807932 · Heinrich-Heine University, Duesseldorf · Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Score 0.9 = 0.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT05805605 · Masonic Cancer Center, University of Minnesota · Allo HSCT Using RIC and PTCy for Hematological Diseases